Setmelanotide (RM-493)

Synonyms: BIM-22493, CAM 4072

Setmelanotide (RM-493, BIM-22493, CAM 4072) is a cyclic peptide full agonist of melanocortin-4 receptor (MC4R) with an EC50 of 0.27 nM and a Ki of 2.1 nM.

Setmelanotide (RM-493) Chemical Structure

Setmelanotide (RM-493) Chemical Structure

CAS No. 920014-72-8

Purity & Quality Control

Setmelanotide (RM-493) Related Products

Biological Activity

Description

Setmelanotide (RM-493, BIM-22493, CAM 4072) is a cyclic peptide full agonist of melanocortin-4 receptor (MC4R) with an EC50 of 0.27 nM and a Ki of 2.1 nM.

Targets
MC4R [1] MC4R [1]
0.27 nM(EC50) 2.1 nM(Ki)
In vitro
In vitro

Setmelanotide decreases TNF-α/IFN-γ-induced chemokine expression in astrocytes and increases IL-6 and IL-11 mRNA and protein secretion via MC4R. Setmelanotide Induces CREB phosphorylation in astrocytes and setmelanotide treated astrocytes secrete factors that are able to modulate macrophage polarization into an anti-inflammatory phenotype.[2]

Cell Research Cell lines U373 astrocytoma cells
Concentrations 0.001 μM –10 μM
Incubation Time 1h, 4 h
Method

Cells were treated with 0.001–10 μM setmelanotide for 1 h and thereafter with TNF-α and IFN-γ for 4 h. For blocking experiments, 10 μM SHU9119 (26) was added 30 min before addition of setmelanotide during 4 h. Astrocytes stimulate with setmelanotide and or SHU9119 (10 μM) for 4 h, replace the medium with macrophage culture medium and add the medium to the macrophages 24 h thereafter. From the medium, 100 μL is collected in Eppendorf tubes and stored at −80°C for ELISA assays.

In Vivo
In vivo

RM-493 co-treatment enhances weight loss in DIO mice and hypothalamic Glp-1r expression is higher in mice treated with the combination therapy after both acute and chronic treatment. Adjunctive administration of RM-493 improves glucose tolerance and insulin sensitivity, lowers fasting levels of glucose and insulin and decreases cholesterol levels beyond what can be achieved with the corresponding mono-therapies.[3]

Animal Research Animal Models Diet-induced obese mice
Dosages 3.6 μmol/kg/day
Administration s.c.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05774756 Enrolling by invitation
Hypothalamic Obesity
Rhythm Pharmaceuticals Inc.
April 26 2023 Phase 3
NCT05093634 Recruiting
Obesity|Genetic Obesity
Rhythm Pharmaceuticals Inc.
December 10 2021 Phase 3
NCT04725240 Completed
Hypothalamic Obesity
Rhythm Pharmaceuticals Inc.
June 7 2021 Phase 2
NCT03651765 Active not recruiting
Obesity Associated With Defects in Leptin-melanocortin Pathway
Rhythm Pharmaceuticals Inc.
July 15 2018 Phase 2|Phase 3
NCT03013543 Completed
Genetic Obesity|Obesity|Obesity Due to Melanocortin 4 Receptor Deficiency
Rhythm Pharmaceuticals Inc.
February 10 2017 Phase 2

Chemical Information & Solubility

Molecular Weight 1117.31 Formula
C49H68N18O9S2
CAS No. 920014-72-8 SDF --
Smiles CC1NC(=O)C(CSSCC(NC(=O)C(CC2=C[NH]C3=CC=CC=C23)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CN=C[NH]5)NC1=O)C(N)=O)NC(=O)C(CCCN=C(N)N)NC(C)=O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 100 mg/mL ( (89.5 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Setmelanotide (RM-493) | Setmelanotide (RM-493) ic50 | Setmelanotide (RM-493) price | Setmelanotide (RM-493) cost | Setmelanotide (RM-493) solubility dmso | Setmelanotide (RM-493) purchase | Setmelanotide (RM-493) manufacturer | Setmelanotide (RM-493) research buy | Setmelanotide (RM-493) order | Setmelanotide (RM-493) mouse | Setmelanotide (RM-493) chemical structure | Setmelanotide (RM-493) mw | Setmelanotide (RM-493) molecular weight | Setmelanotide (RM-493) datasheet | Setmelanotide (RM-493) supplier | Setmelanotide (RM-493) in vitro | Setmelanotide (RM-493) cell line | Setmelanotide (RM-493) concentration | Setmelanotide (RM-493) nmr